Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 6/20 | 0.38 |
| ▸ | CA2 | P00918 | 6/20 | 0.38 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8260176 | 1.00 | TDP1 (0.43) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL4473309 | 1.00 | TDP1 (0.43) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL22121480 | 0.98 | TDP1 (0.42) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL21616394 | 0.98 | TDP1 (0.42) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18262010 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18262007 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL18487257 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL17302431 | 0.86 | TDP1 (0.41) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL23992116 | 0.84 | TDP1 (0.30) | TDP1 | |
| SCHEMBL661593 | 0.83 | TDP1 (0.49) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920172-B | Interferon-stimulated protein targeted compound, radioactive marker thereof, and preparation methods and applications of interferon-stimulated protein targeted compound and radioactive marker | 厦门大学 | 2022-03-22 | — | — | CN | claimed |
| CN-112920172-A | Interferon-stimulated protein targeted compound, radioactive marker thereof, and preparation methods and applications of interferon-stimulated protein targeted compound and radioactive marker | 厦门大学 | 2021-06-08 | — | — | CN | claimed |
| EP-3919488-B1 | IMMUNOMODULATOR | HITGEN INC (CN) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024200838-A1 | NEW ODILORHABDINS ANALOGUES AS ANTIBIOTICS AGAINST MULTI-RESISTANT BACTERIA | NOSOPHARM (FR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024174863-A1 | STING AGONIST AND PREPARATION METHOD AND MEDICAL USE THEREOF | 深圳众格生物科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-20240269305-A1 | STING AGONIST SUITABLE AS PAYLOAD OF ANTIBODY DRUG CONJUGATE | HITGEN INC (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-112300227-B | Heterocyclic amide compound, and preparation method and application thereof | 江西济民可信集团有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-114174285-B | Heterocyclic amide compound, and preparation method and application thereof | 上海济煜医药科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116829551-A | Immunomodulatory antibody drug conjugates | 思进公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-111417630-B | Modulators of interferon gene stimulating factor (STING) | 葛兰素史克知识产权开发有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-113444023-B | Synthesis method and application of tert-butoxycarbonyl protected ammonia compound | 成都先导药物开发股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-111499617-A | Immunomodulator | 成都先导药物开发股份有限公司 | 2020-08-07 | — | — | CN | disclosed |
| WO-2020156363-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2020-08-06 | — | — | WO | disclosed |
| CN-111417630-A | Modulators of interferon gene stimulating factor (STING) | 葛兰素史克知识产权开发有限公司 | 2020-07-14 | — | — | CN | disclosed |
| CN-111194214-A | Methods of administering STING agonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-05-22 | — | — | CN | disclosed |
| US-7511077-B2 | Diamine calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-31 | — | — | US | disclosed |
| EP-1846365-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006084369-A9 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD (CA) | 2007-01-11 | — | — | WO | disclosed |
| US-20060235050-A1 | Diamine calcium channel blockers | NUEROMED TECHNOLOGIES, INC. (CA) | 2006-10-19 | — | — | US | disclosed |
| WO-2006084369-A1 | DIAMINE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235050-A1 | Diamine calcium channel blockers | CACNA1G, CACNA1H, CACNA1I | TDP1 1412/4885MAOA 834/4885MAOB 535/4885 |
| US-20240269305-A1 | STING AGONIST SUITABLE AS PAYLOAD OF ANTIBODY DRUG CONJUGATE | STING1, TBK1, CGAS | TDP1 588/4885MAOA 2139/4885MAOB 2936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.